

## Putting NICE guidance into practice

### **Costing statement: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)**

Published: October 2015

This technology is commissioned by NHS England.

The Department of Health and Merck Sharp & Dohme have agreed that pembrolizumab will be available to the NHS with a patient access scheme which makes it available with a discount. The size of the discount is commercial in confidence. It is the responsibility of the company to communicate details of the discount to the relevant NHS organisations. Any enquiries from NHS organisations about the patient access scheme should be directed to Keiron Hughes ([keiron.hughes@merck.com](mailto:keiron.hughes@merck.com)).

There is a local costing template that supports this guidance. If provider organisations wish to use this template, please contact [ResourceImpactAssessment@nice.org.uk](mailto:ResourceImpactAssessment@nice.org.uk).

This costing statement accompanies the NICE technology appraisal guidance on [pembrolizumab for treating advanced melanoma after disease progression with ipilimumab](#) and should be read in conjunction with it. See [terms and conditions](#) on the NICE website.

© National Institute for Health and Care Excellence, 2015. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.